Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
Amanda Cano(Instituto de Salud Carlos III), Merçé Boada(Instituto de Salud Carlos III), Agustı́n Ruiz(The University of Texas at San Antonio Health Science Center), Giovanni Tosi(University of Modena and Reggio Emilia), Jason Thomas Duskey(University of Modena and Reggio Emilia), Patric Turowski(Institute of Ophthalmology), Miren Ettcheto(Biomedical Research Networking Center on Neurodegenerative Diseases), Eliana B. Souto(University of Coimbra), Antoni Camins(Biomedical Research Networking Center on Neurodegenerative Diseases), Elena Sánchez‐López(Instituto de Salud Carlos III), María L. García(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marta Marquié(Biomedical Research Networking Center on Neurodegenerative Diseases)
Cited by 122
Related Papers
Metal-Based Nanoparticles as Antimicrobial Agents: An Overview
|Nanomaterials|2020|1.4k
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease
|Nature Genetics|2017|1.1k
Therapeutic potential of venom peptides
|Nature Reviews Drug Discovery|2003|786
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery
|International Journal of Pharmaceutics|2004|664
Validating novel tau positron emission tomography tracer <scp>[F‐18]‐AV‐1451 (T807)</scp> on postmortem brain tissue
|Annals of Neurology|2015|626